Business Context and Reporting Period
This Form 8-K filing by Anthem, Inc. (now Elevance Health, Inc.) reports a debt financing event that closed on March 2, 2018, pursuant to an Underwriting Agreement dated February 27, 2018. The filing details the issuance of new senior notes and the exchange of existing remarketable notes.
Key Financial Metrics and Transaction Details
- New Debt Issuance: The Company sold $850 million aggregate principal amount of 4.550% Notes due 2048.
- Net Proceeds: The Company received approximately $835.2 million from the sale of the 2048 Notes after deducting underwriting discounts and offering expenses.
- Exchange Transaction: Selling Securityholders exchanged $1,250 million of 1.90% remarketable subordinated notes due 2028 for new 4.101% Notes due 2028. The Company received no proceeds from this portion of the transaction.
- Interest Rate Reset: As a result of the remarketing, the annual interest rate on the exchanged notes was reset to 4.324% prior to the exchange.
- Use of Proceeds: Net proceeds are designated for working capital, general corporate purposes, repayment of short-term and long-term debt, share repurchases, and funding acquisitions.
Material Changes and Debt Structure
The filing represents a material change in the Company's capital structure through the addition of long-term debt and the modification of existing subordinated debt terms. The 2028 Notes mature on March 1, 2028, and the 2048 Notes mature on March 1, 2048. Interest is payable semi-annually in arrears, commencing September 1, 2018. The Indenture governing these notes does not prohibit or limit the incurrence of additional indebtedness.
Outlook, Risks, and Covenants
- Redemption Rights: The Company may redeem the 2028 Notes at par on or after May 1, 2020, and the 2048 Notes at par on or after September 1, 2047. Prior to these dates, redemption is permitted at a price equal to the greater of 100% of principal or the present value of remaining payments discounted at the Treasury Rate plus a spread (20 basis points for 2028 Notes; 25 basis points for 2048 Notes).
- Change of Control: Upon a change of control and a downgrade of the 2048 Notes below investment grade by Moody's, S&P, and Fitch, the Company must offer to repurchase the 2048 Notes at 101% of principal plus accrued interest. No such repurchase obligation exists for the 2028 Notes.
- Events of Default: Include failure to pay principal or interest, breach of indenture terms for 90 days after notice, and bankruptcy or insolvency proceedings.
Investor Verification Checklist
- Verify the exact net proceeds of $835.2 million against the Company's cash flow statement for the quarter ending March 31, 2018.
- Confirm the cancellation of the $1,250 million Remarketable Notes and the issuance of the new 2028 Notes in the Company's debt schedule.
- Review the Underwriting Agreement (Exhibit 1.1) for specific details on underwriting discounts and commissions.
- Monitor the Company's credit ratings to assess the risk of triggering the mandatory repurchase provision for the 2048 Notes.
- Check subsequent filings for the actual deployment of proceeds toward debt repayment or share repurchases as stated in the intended use.